#1 Clinical Trials Search in Europe

Ceftazidime Pentahydrate

This article explores the use of Ceftazidime Pentahydrate in clinical trials for treating various bacterial infections, particularly in critically ill patients with sepsis and bronchiectasis. We’ll examine how this antibiotic is being studied to optimize dosing strategies and improve patient outcomes in intensive care settings.

Table of Contents

What is Ceftazidime Pentahydrate?

Ceftazidime Pentahydrate is a third-generation cephalosporin antibiotic. It belongs to a class of drugs called beta-lactam antibiotics, which work by preventing bacteria from forming their cell walls, ultimately leading to their destruction[1]. This medication is primarily used to treat various bacterial infections, particularly those caused by gram-negative bacteria.

Medical Uses

Ceftazidime Pentahydrate is prescribed for several types of infections, including:

  • Bronchiectasis: A condition where the airways of the lungs become damaged and widened, leading to a buildup of mucus and increased risk of infection[1].
  • Hospital-acquired sepsis: A severe, potentially life-threatening condition caused by the body’s extreme response to an infection that has been acquired in a hospital setting[2].
  • Respiratory tract infections: Including pneumonia and other lung infections[3].
  • Urinary tract infections: Particularly those caused by resistant bacteria[3].
  • Skin and soft tissue infections: Especially those caused by gram-negative bacteria[3].

How is it Administered?

Ceftazidime Pentahydrate is typically administered in the following ways:

  • Intravenous (IV) injection: The medication is injected directly into a vein[1].
  • Intramuscular (IM) injection: The drug is injected into a muscle[1].
  • Continuous infusion: In some cases, particularly in intensive care settings, the drug may be administered as a continuous infusion over a period of time[3].

Dosage Information

The dosage of Ceftazidime Pentahydrate can vary depending on the type and severity of the infection, as well as the patient’s age, weight, and kidney function. However, some general dosage guidelines from the clinical trials include:

  • For severe infections in adults, doses can range from 1 to 6 grams per day[1].
  • In some cases of severe sepsis, doses up to 12 grams per day have been studied[3].
  • The duration of treatment typically ranges from 3 to 14 days, depending on the infection and the patient’s response to treatment[1][3].

It’s crucial to follow your doctor’s instructions regarding dosage and duration of treatment.

Current Clinical Trials

Ceftazidime Pentahydrate is currently being studied in several clinical trials:

  • ANTEIPA Study: This trial is comparing different antibiotic regimens, including Ceftazidime, for treating early airway infections in adults with bronchiectasis[1].
  • BuLLSEYE Study: This study is investigating optimal dosing strategies for beta-lactam antibiotics, including Ceftazidime, in critically ill patients with sepsis[2].
  • BICCS Study: This trial is comparing continuous versus intermittent infusion of beta-lactam antibiotics, including Ceftazidime, in patients with hospital-acquired sepsis[3].

Potential Side Effects

Like all medications, Ceftazidime Pentahydrate can cause side effects. Common side effects may include:

  • Nausea or vomiting
  • Diarrhea
  • Headache
  • Skin rash or itching
  • Pain or inflammation at the injection site

More serious side effects, though rare, can include severe allergic reactions, kidney problems, or Clostridium difficile-associated diarrhea. If you experience any severe or persistent side effects, contact your healthcare provider immediately[1][2][3].

Precautions and Contraindications

Ceftazidime Pentahydrate should be used with caution in certain situations:

  • Allergies: If you have a known allergy to cephalosporin antibiotics, penicillins, or other beta-lactam antibiotics, inform your doctor before taking Ceftazidime[3].
  • Kidney problems: The dosage may need to be adjusted in patients with impaired kidney function[2].
  • Pregnancy and breastfeeding: Consult your doctor if you are pregnant, planning to become pregnant, or breastfeeding[1].
  • Other medications: Inform your doctor about all medications you are taking, as Ceftazidime may interact with certain drugs[3].

Remember, this information is not exhaustive, and you should always consult with your healthcare provider for personalized medical advice and information specific to your condition and treatment plan.

Aspect Details
Drug Name Ceftazidime Pentahydrate
Drug Class Third-generation cephalosporin antibiotic
Primary Uses in Trials Treatment of sepsis, bronchiectasis with Pseudomonas aeruginosa infection
Administration Methods Intravenous injection, continuous infusion, intermittent dosing
Dosage Range 6-12 grams per day, up to 84 grams total over treatment course
Treatment Duration 3-14 days, depending on the study and condition
Key Objectives Optimize dosing strategies, improve clinical outcomes, assess safety and efficacy
Primary Endpoints Mortality rates, clinical cure rates, microbiological eradication
Patient Population Adult patients (≥18 years) with severe infections requiring ICU care
Combination Therapies Often studied in combination with other antibiotics (e.g., fluoroquinolones, aminoglycosides)

FAQ

  • What is Ceftazidime Pentahydrate? Ceftazidime Pentahydrate is a third-generation cephalosporin antibiotic used to treat various bacterial infections. It's particularly effective against gram-negative bacteria and is often used in hospital settings for serious infections.
  • How is Ceftazidime Pentahydrate being studied in clinical trials? Clinical trials are investigating different dosing strategies for Ceftazidime Pentahydrate, including continuous infusion versus intermittent dosing, and its use in combination with other antibiotics. The goal is to improve treatment outcomes for critically ill patients with sepsis and other severe infections.
  • What types of patients are included in these clinical trials? The trials primarily focus on adult patients (18 years and older) with severe infections such as hospital-acquired sepsis, bronchiectasis with Pseudomonas aeruginosa infection, and other critical illnesses requiring intensive care unit (ICU) admission.
  • What are the main objectives of these clinical trials? The main objectives include comparing different antibiotic regimens, optimizing dosing strategies, improving clinical outcomes such as mortality rates and infection eradication, and assessing the safety and efficacy of Ceftazidime Pentahydrate in various treatment approaches.
  • How is the effectiveness of Ceftazidime Pentahydrate measured in these trials? Effectiveness is measured through various endpoints, including mortality rates, clinical cure rates, microbiological eradication of infections, length of hospital stay, and pharmacokinetic/pharmacodynamic target attainment. Researchers also monitor for adverse events and the development of antibiotic resistance.

Ongoing Clinical Trials on Ceftazidime Pentahydrate

  • Study on Optimizing Initial Dosing of Flucloxacillin and Drug Combination for Critically Ill Patients with Sepsis in the ICU

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study Comparing Ciprofloxacin, Colistimethate Sodium, and Ceftazidime for Treating Early Airway Infection in Adults with Bronchiectasis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of antibiotic treatment effectiveness in critically ill patients receiving drug combination therapy

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on the Effectiveness and Safety of Amoxicillin, Clavulanic Acid, and Metronidazole for Treating Acute Appendicitis in Children Aged 7 to 18

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Latvia

  • Study Comparing Different Antibiotic Treatments for ICU Patients with Hospital-Acquired Sepsis: Focus on Cefepime and Drug Combination

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Ceftazidime Pentahydrate: A third-generation cephalosporin antibiotic used to treat various bacterial infections, particularly effective against gram-negative bacteria.
  • Sepsis: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation and organ dysfunction.
  • Bronchiectasis: A chronic lung condition where the airways become abnormally widened, leading to a build-up of excess mucus that makes the lungs more vulnerable to infection.
  • Pseudomonas aeruginosa: A type of bacteria that can cause severe hospital-acquired infections, particularly in patients with weakened immune systems.
  • Continuous infusion: A method of administering medication where the drug is given constantly over a period of time, rather than in intermittent doses.
  • Pharmacokinetic/Pharmacodynamic (PK/PD): The study of how a drug moves through the body (pharmacokinetics) and its effects on the body (pharmacodynamics), used to optimize dosing strategies.
  • Minimum Inhibitory Concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacterium, used to determine the effectiveness of the antibiotic against specific bacteria.
  • Multidrug-resistant (MDR): Bacteria that have developed resistance to multiple types of antibiotics, making infections more difficult to treat.
  • SOFA score: Sequential Organ Failure Assessment score, a scoring system used to determine the extent of a person's organ function or rate of failure in the ICU.
  • Eradication rate: The percentage of patients in whom the infection-causing bacteria are completely eliminated after treatment.

References

  1. http://clinicaltrials.eu/trial/study-comparing-ciprofloxacin-colistimethate-sodium-and-ceftazidime-for-treating-early-airway-infection-in-adults-with-bronchiectasis/
  2. http://clinicaltrials.eu/trial/study-on-optimizing-initial-dosing-of-flucloxacillin-and-drug-combination-for-critically-ill-patients-with-sepsis-in-the-icu/
  3. http://clinicaltrials.eu/trial/study-comparing-different-antibiotic-treatments-for-icu-patients-with-hospital-acquired-sepsis-focus-on-cefepime-and-drug-combination/